These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 16166596)

  • 41. Insulin-like growth factor-1 receptor and ErbB kinase inhibitor combinations block proliferation and induce apoptosis through cyclin D1 reduction and Bax activation.
    Wilsbacher JL; Zhang Q; Tucker LA; Hubbard RD; Sheppard GS; Bamaung NY; Fidanze SD; Wang GT; Hu X; Davidsen SK; Bell RL; Wang J
    J Biol Chem; 2008 Aug; 283(35):23721-30. PubMed ID: 18559346
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth.
    Girnita A; Girnita L; del Prete F; Bartolazzi A; Larsson O; Axelson M
    Cancer Res; 2004 Jan; 64(1):236-42. PubMed ID: 14729630
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
    Oh SH; Jin Q; Kim ES; Khuri FR; Lee HY
    Clin Cancer Res; 2008 Mar; 14(5):1581-9. PubMed ID: 18316583
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Insulin-like growth factor 1 receptor is a prognostic factor in classical Hodgkin lymphoma.
    Liang Z; Diepstra A; Xu C; van Imhoff G; Plattel W; Van Den Berg A; Visser L
    PLoS One; 2014; 9(1):e87474. PubMed ID: 24489919
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.
    Yasui H; Hideshima T; Hamasaki M; Roccaro AM; Shiraishi N; Kumar S; Tassone P; Ishitsuka K; Raje N; Tai YT; Podar K; Chauhan D; Leoni LM; Kanekal S; Elliott G; Munshi NC; Anderson KC
    Blood; 2005 Jul; 106(2):706-12. PubMed ID: 15802527
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma.
    Yin S; Girnita A; Strömberg T; Khan Z; Andersson S; Zheng H; Ericsson C; Axelson M; Nistér M; Larsson O; Ekström TJ; Girnita L
    Neuro Oncol; 2010 Jan; 12(1):19-27. PubMed ID: 20150364
    [TBL] [Abstract][Full Text] [Related]  

  • 47. IGF-1R tyrosine kinase expression and dependency in clones of IGF-1R knockout cells (R-).
    Rosengren L; Vasilcanu D; Vasilcanu R; Fickenscher S; Sehat B; Natalishvili N; Naughton S; Yin S; Girnita A; Girnita L; Axelson M; Larsson O
    Biochem Biophys Res Commun; 2006 Sep; 347(4):1059-66. PubMed ID: 16857168
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells.
    Girnita A; All-Ericsson C; Economou MA; Aström K; Axelson M; Seregard S; Larsson O; Girnita L
    Acta Ophthalmol; 2008 Nov; 86 Thesis 4():26-34. PubMed ID: 19032679
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism.
    Dai Y; Landowski TH; Rosen ST; Dent P; Grant S
    Blood; 2002 Nov; 100(9):3333-43. PubMed ID: 12384435
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.
    Haluska P; Carboni JM; Loegering DA; Lee FY; Wittman M; Saulnier MG; Frennesson DB; Kalli KR; Conover CA; Attar RM; Kaufmann SH; Gottardis M; Erlichman C
    Cancer Res; 2006 Jan; 66(1):362-71. PubMed ID: 16397250
    [TBL] [Abstract][Full Text] [Related]  

  • 51. IGF-1 receptor inhibition by picropodophyllin in medulloblastoma.
    Ohshima-Hosoyama S; Hosoyama T; Nelon LD; Keller C
    Biochem Biophys Res Commun; 2010 Sep; 399(4):727-32. PubMed ID: 20692232
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.
    Sprynski AC; Hose D; Caillot L; Réme T; Shaughnessy JD; Barlogie B; Seckinger A; Moreaux J; Hundemer M; Jourdan M; Meissner T; Jauch A; Mahtouk K; Kassambara A; Bertsch U; Rossi JF; Goldschmidt H; Klein B
    Blood; 2009 May; 113(19):4614-26. PubMed ID: 19228610
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Connexin 30 downregulates Insulin-like growth factor receptor-1, abolishes Erk and potentiates effects of an IGF-R inhibitor in a glioma cell line.
    Arun S; Vanisree AJ; Ravisankar S
    Brain Res; 2016 Jul; 1643():80-90. PubMed ID: 27130897
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effect of forced expression of mutated K-RAS gene on gastrointestinal cancer cell lines and the IGF-1R targeting therapy.
    Matsunaga Y; Adachi Y; Sasaki Y; Koide H; Motoya M; Nosho K; Takagi H; Yamamoto H; Sasaki S; Arimura Y; Tokino T; Carbone DP; Imai K; Shinomura Y
    Mol Carcinog; 2017 Feb; 56(2):515-526. PubMed ID: 27312358
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth.
    Ge NL; Rudikoff S
    Blood; 2000 Oct; 96(8):2856-61. PubMed ID: 11023522
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells.
    Girnita A; All-Ericsson C; Economou MA; Aström K; Axelson M; Seregard S; Larsson O; Girnita L
    Clin Cancer Res; 2006 Feb; 12(4):1383-91. PubMed ID: 16489097
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Heterogeneity of neuroblastoma cell lines in insulin-like growth factor 1 receptor/Akt pathway-mediated cell proliferative responses.
    Qi L; Toyoda H; Shankar V; Sakurai N; Amano K; Kihira K; Iwasa T; Deguchi T; Hori H; Azuma E; Gabazza EC; Komada Y
    Cancer Sci; 2013 Sep; 104(9):1162-71. PubMed ID: 23710710
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
    Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
    Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line.
    Ogawa M; Nishiura T; Oritani K; Yoshida H; Yoshimura M; Okajima Y; Ishikawa J; Hashimoto K; Matsumura I; Tomiyama Y; Matsuzawa Y
    Cancer Res; 2000 Aug; 60(15):4262-9. PubMed ID: 10945640
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
    Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
    Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.